AGM/EGMJun 25, 2026, 08:07 AM
NextCure Stockholders Approve Amended Incentive Plan, Elect Directors
AI Summary
NextCure, Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026. Key outcomes included the approval of the Amended and Restated 2019 Omnibus Incentive Plan, which increases the maximum number of shares authorized for issuance by 80,000. Stockholders also elected two Class I directors, ratified Ernst & Young LLP as the independent auditor for 2026, and approved, on an advisory basis, the compensation paid to named executive officers.
Key Highlights
- Stockholders approved the Amended and Restated 2019 Omnibus Incentive Plan.
- The A&R 2019 Plan increases authorized shares by 80,000.
- The plan's evergreen provision now bases annual increase on fully diluted outstanding shares.
- Anne Borgman, M.D. and John G. Houston, PH.D. were elected as Class I directors.
- Ernst & Young LLP was ratified as the independent auditor for fiscal year 2026.
- Stockholders approved, on an advisory basis, executive compensation.
Price Impact
More from NXTC